Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2006 1
2012 3
2014 1
2015 2
2016 5
2017 25
2018 36
2019 27
2020 23
2021 13
2022 8
2023 17
2024 22
2025 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Valbenazine.
[No authors listed] [No authors listed] 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Sep 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 37748010 Free Books & Documents. Review.
No information is available on the use of valbenazine during breastfeeding in humans. Based on animal studies, the manufacturer recommends that breastfeeding be avoided during valbenazine therapy and for 5 days after the final dose....
No information is available on the use of valbenazine during breastfeeding in humans. Based on animal studies, the manufacturer recom …
Valbenazine for the Treatment of Adults with Tardive Dyskinesia.
Gupta H, Moity AR, Jumonville A, Kaufman S, Edinoff AN, Kaye AD. Gupta H, et al. Health Psychol Res. 2021 Jun 18;9(1):24929. doi: 10.52965/001c.24929. eCollection 2021. Health Psychol Res. 2021. PMID: 35106396 Free PMC article. Review.
This leads to decreased dopaminergic activation of the striatal motor pathway. The FDA approved Valbenazine in 2017 to treat tardive dyskinesia in adults and needs to be evaluated with existing therapeutic approaches. ...Once symptom onset has occurred, these movement abno …
This leads to decreased dopaminergic activation of the striatal motor pathway. The FDA approved Valbenazine in 2017 to treat tardive …
Valbenazine for Tardive Dyskinesia.
Freudenreich O, Remington G. Freudenreich O, et al. Clin Schizophr Relat Psychoses. 2017 Summer;11(2):113-119. doi: 10.3371/CSRP.OFGR.071717. Clin Schizophr Relat Psychoses. 2017. PMID: 28742396 Review.
In this New Drug Review, we summarize the basic pharmacology and clinical trial results for valbenazine. Valbenazine is a modified metabolite of the vesicular monoamine transporter 2 (VMAT-2) inhibitor tetrabenazine, which is approved for the treatment of the hyperk …
In this New Drug Review, we summarize the basic pharmacology and clinical trial results for valbenazine. Valbenazine is a modi …
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D; Huntington Study Group KINECT-HD Collaborators. Furr Stimming E, et al. Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
Of 128 randomly assigned participants, 125 were included in the full-analysis set (64 assigned to valbenazine, 61 assigned to placebo) and 127 were included in the safety-analysis set (64 assigned to valbenazine, 63 assigned to placebo). ...No suicidal behaviour or …
Of 128 randomly assigned participants, 125 were included in the full-analysis set (64 assigned to valbenazine, 61 assigned to placebo …
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF. Hauser RA, et al. Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21. Am J Psychiatry. 2017. PMID: 28320223 Clinical Trial.
Participants were randomly assigned in a 1:1:1 ratio to once-daily placebo, valbenazine at 40 mg/day, or valbenazine at 80 mg/day. The primary efficacy endpoint was change from baseline to week 6 in the 80 mg/day group compared with the placebo group on the Abnormal …
Participants were randomly assigned in a 1:1:1 ratio to once-daily placebo, valbenazine at 40 mg/day, or valbenazine at 80 mg/ …
Valbenazine Therapy and CYP2D6 Genotype.
Kane M. Kane M. 2024 Nov 13 [updated 2025 Jan 17]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. 2024 Nov 13 [updated 2025 Jan 17]. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012–. PMID: 39565887 Free Books & Documents. Review.
Valbenazine (marketed as Ingrezza in the US and Dysval in Japan) is a vesicular monoamine transporter 2 (VMAT2) inhibitor used in the treatment of tardive dyskinesia (TD) or Huntington disease (HD) chorea (1, 2). ...The active valbenazine metabolite is further metab …
Valbenazine (marketed as Ingrezza in the US and Dysval in Japan) is a vesicular monoamine transporter 2 (VMAT2) inhibitor used in the …
Valbenazine for the treatment of tardive dyskinesia.
Müller T. Müller T. Expert Rev Neurother. 2017 Dec;17(12):1135-1144. doi: 10.1080/14737175.2017.1386556. Epub 2017 Oct 12. Expert Rev Neurother. 2017. PMID: 28971695 Review.
Valbenazine and particularly its metabolite inhibit vesicular monoamine transporter 2 function. Once daily intake of valbenazine ameliorated the severity of tardive dyskinesia. The chiral purity of valbenazine circumvents generation of the (-)alpha and (+) an …
Valbenazine and particularly its metabolite inhibit vesicular monoamine transporter 2 function. Once daily intake of valbenazine …
Valbenazine: First Global Approval.
Kim ES. Kim ES. Drugs. 2017 Jul;77(10):1123-1129. doi: 10.1007/s40265-017-0770-9. Drugs. 2017. PMID: 28578484 Review.
Valbenazine (Ingrezza) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by Neurocrine Biosciences for the treatment of various central nervous system disorders. ...This article summarizes the milestones in the develo …
Valbenazine (Ingrezza) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by N …
Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
Khorassani F, Luther K, Talreja O. Khorassani F, et al. Am J Health Syst Pharm. 2020 Jan 24;77(3):167-174. doi: 10.1093/ajhp/zxz299. Am J Health Syst Pharm. 2020. PMID: 31974564 Review.
PURPOSE: The purpose of this review is to summarize the current evidence for valbenazine and deutetrabenazine use for the treatment of tardive dyskinesia (TD). SUMMARY: A literature search was conducted to gather relevant data regarding the use of valbenazine and de …
PURPOSE: The purpose of this review is to summarize the current evidence for valbenazine and deutetrabenazine use for the treatment o …
Valbenazine and Deutetrabenazine for Tardive Dyskinesia.
Touma KTB, Scarff JR. Touma KTB, et al. Innov Clin Neurosci. 2018 Jun 1;15(5-6):13-16. Innov Clin Neurosci. 2018. PMID: 30013814 Free PMC article. Review.
Although TD is medication-induced, patients who have responded well to antipsychotics might not be candidates for dose reduction or discontinuation due to a risk of psychiatric decompensation. Valbenazine and deutetrabenazine were recently approved by the FDA for the treat …
Although TD is medication-induced, patients who have responded well to antipsychotics might not be candidates for dose reduction or disconti …
183 results